Utah Medical Products Inc. develops, manufactures and markets disposable and reusable specialty medical devices, with a stated focus on health care for women and babies. Its products are used in areas such as blood pressure monitoring, blood collection, electrosurgery, gynecology, neonatal critical care, perinatology and urology, serving hospitals, outpatient clinics and physicians' offices.
Company updates commonly cover quarterly and annual financial performance, domestic and outside-U.S. sales trends, foreign-currency effects, product-category demand, OEM and distributor relationships, and profit margins. Recurring corporate actions include quarterly cash dividends, open-market share repurchases when disclosed, board appointments and other governance updates for the Nasdaq-listed common stock.
Utah Medical Products (UTMD) corrected the weekday for its tender offer’s scheduled October 7 expiration from Tuesday to Wednesday.
The offer is scheduled to expire at 5:00 p.m. New York City time, unless UTMD extends it. The company is offering to purchase up to 650,000 common shares at $75.00 per share. Its SEC Form TO Offer to Purchase and Letter of Transmittal contain the offer conditions.
Utah Medical Products (UTMD) launched a tender offer on September 24, 2026, to buy up to 650,000 common shares.
The $75.00 per-share price is 17% above the stock's average daily closing price over the last twelve months and 21% above its average over the last twenty-four months. The offer is scheduled to expire at 5:00 p.m. New York City time on October 7, unless extended. The board approved the offer, but neither it nor the company recommends whether shareholders should tender.
First-half 2026 sales were 12% lower and net profits were 13% lower than in the same period of 2025. EBITDA for the last half of 2025 and first half of 2026 was $15,703,744.
Utah Medical Products (UTMD) plans a cash tender offer to repurchase up to 650,000 shares, about 20% of its outstanding stock, at $75.00 per share.
The price is 17% above the average daily closing price over the last twelve months and 21% above the two-year average, and is just below the two-year intraday high of $75.75. The offer is expected to commence on September 22, 2026, or as soon as possible thereafter, and will expire fifteen business days later unless extended. If oversubscribed, UTMD will first buy all shares tendered by holders of fewer than 100 shares, then purchase remaining tendered shares on a pro rata basis. The company may purchase more than 650,000 shares, and the offer is not conditioned on any minimum tender.
Utah Medical Products (Nasdaq: UTMD), through its wholly owned UK subsidiary Femcare, has acquired the entire ordinary share capital of Orion Medical Supplies, a UK-based niche assembler and distributor of Harm Reduction medical device kits serving the UK and European markets. Orion’s products, which aim to reduce blood-borne infections, drug-related injuries and negative social impacts, are well accepted by the UK NHS and other European organizations where Femcare and UTMD already distribute proprietary devices.
According to Utah Medical Products, the acquisition is expected to be accretive, adding about $6 million to current consolidated annual sales and benefiting from leverage of Femcare’s existing infrastructure, substantially diluting overhead as a percentage of UK sales. The purchase price was £3.6 million, funded from cash reserves, and Orion’s operations will be transitioned into Femcare’s Romsey facilities after a transition period. Additional acquisition-related risk factors will be detailed in UTMD’s Q3 2026 Form 10-Q, expected by October 15.
Utah Medical Products (Nasdaq: UTMD) announced that its Board of Directors approved a quarterly cash dividend of $0.31 per share of common stock. The dividend is payable on October 5, 2026 to shareholders of record as of September 17, 2026, representing a 1.6% increase over the dividend declared in the same quarter of the prior year.
Utah Medical Products (Nasdaq: UTMD) reported 2Q 2026 worldwide sales of $8,529, down $1,424 or 14.3% from 2Q 2025, and 1H 2026 sales of $17,252, down $2,411 or 12.3% year over year. The decline was mainly due to zero 2026 sales to its two previously largest customers, compared with $1,066 in 2Q 2025 and $1,923 in 1H 2025. In 1H 2026, sales to new biopharma customers reached $211, slower than planned.
2Q 2026 gross margin was 55.8% versus 56.2% a year earlier, while 1H 2026 gross margin improved to 58.2% from 56.6%. Operating income was $2,649 in 2Q (margin 31.1%) and $5,215 in 1H (margin 30.2%), down 17.1% and 17.9% respectively, affected by higher U.S. litigation costs. Net income margins were 31.5% in 2Q and 30.7% in 1H. UTMD ended June 30, 2026 with $87.5 million in cash and investments, no debt, after paying $2.0 million in dividends, repurchasing $0.2 million of stock and investing $0.3 million in capex. Management now projects a 10–13% decline in 2026 sales versus 2025.
Utah Medical Products (Nasdaq: UTMD) announced a quarterly cash dividend of $0.31 per share, payable on July 3, 2026 to shareholders of record at the close of business on June 17, 2026. This reflects a 1.6% increase versus the same quarter last year.
The company develops and sells disposable and reusable specialty medical devices focused on maternal and neonatal care in over 100 countries. For more information, visit UTMD's website.
Utah Medical Products (Nasdaq: UTMD) reported 1Q 2026 results: consolidated sales declined 10.2% versus 1Q 2025, GP fell 4.6% to $5,282, OI fell 18.7% to $2,565 (29.4% margin), NI fell 14.4% to $2,604, and EPS was $0.818 (down 11.0%). Cash equivalents were $4.1M higher than March 31, 2025. The company cited lost 1Q 2026 sales to a former China distributor and PendoTECH as principal drivers of lower revenue.
Utah Medical Products (Nasdaq:UTMD) announced a quarterly cash dividend of $0.31 per share, payable April 3, 2026 to shareholders of record at the close of business March 17, 2026. This represents a 1.6% increase versus the same quarter a year earlier.
The company develops and markets specialty disposable and reusable medical devices focused on women and babies and distributes products in over 100 countries. Contact: Brian Koopman, (801) 566-1200.
Utah Medical Products (NYSE:UTMD) reported 2025 results with consolidated revenues of $38.5M, down 5.8% from 2024, and net income down 19%. EPS declined 12%. The company increased year-end cash to $85.8M after $8.4M in share repurchases and $4.0M in dividends.
Major drivers: loss of PendoTECH OEM sales, weaker OUS Filshie device sales, favorable FX partially offset declines, and continued strong gross margins despite higher input and personnel costs.